Bioventus sank -7.68% Friday, compared to the S&P 500's day change of 1.60%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Bioventus has logged a -83.53% 52 week change, compared to -3.7% for the S&P 500
-
BVS has an average analyst rating of hold and is -65.77% away from its mean target price of $6.5 per share
-
Its trailing earnings per share (EPS) is $-2.63, which brings its trailing Price to Earnings (P/E) ratio to -0.85.
-
The company's forward earnings per share (EPS) is $0.2 and its forward P/E ratio is 11.12
-
The company has a Price to Book (P/B) ratio of 0.584
-
The current ratio is currently 1.45, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $15,621,000.00